CC
Casdin Capital Portfolio holdings
AUM $1.1B
1-Year Return
24.98%
This Quarter Return
+59.63%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.69B
AUM Growth
+$748M
(+79%)
Cap. Flow
+$316M
Cap. Flow
% of AUM
18.68%
Top 10 Holdings %
Top 10 Hldgs %
59.6%
Holding
45
New
7
Increased
11
Reduced
10
Closed
3
Top Buys
| 1 |
NVTA
Invitae Corporation
NVTA
|
+$168M |
| 2 |
BNR
Burning Rock Biotech
BNR
|
+$46.7M |
| 3 |
BioLife Solutions
BLFS
|
+$38.9M |
| 4 |
Generation Bio
GBIO
|
+$33.8M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
+$28.3M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
+$22.4M |
| 2 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$13.9M |
| 3 |
Gilead Sciences
GILD
|
+$13.1M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$12.1M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$11.1M |
Sector Composition
| 1 | Healthcare | 81.83% |
| 2 | Materials | 1.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVTA
1
DELISTED
Invitae Corporation
NVTA
| $274M | 16.19% |
9,033,943
+5,555,555
| +160% | +$168M |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $121M | 7.15% |
1,550,000
| – | – |
|
3
Fate Therapeutics
FATE
$111M
| $105M | 6.19% |
3,050,000
+500,000
| +20% | +$17.2M |
|
|
4
Sarepta Therapeutics
SRPT
$1.93B
| $85M | 5.03% |
530,000
-140,000
| -21% | -$22.4M |
|
|
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $84.1M | 4.97% |
870,000
-125,000
| -13% | -$12.1M |
|
6
Alnylam Pharmaceuticals
ALNY
$60.5B
| $81.5M | 4.82% |
550,000
-35,000
| -6% | -$5.18M |
|
|
7
BioLife Solutions
BLFS
$1.24B
| $79.3M | 4.69% |
4,849,524
+2,380,953
| +96% | +$38.9M |
|
|
BLUE
8
DELISTED
bluebird bio
BLUE
| $67.4M | 3.99% |
85,306
| – | – |
|
9
Agios Pharmaceuticals
AGIO
$2.15B
| $57.2M | 3.39% |
1,070,000
| – | – |
|
10
Codexis
CDXS
$222M
| $53.5M | 3.17% |
4,692,732
-381,048
| -8% | -$4.34M |
|
|
BNR
11
Burning Rock Biotech
BNR
$91.5M
| $46.7M | 2.77% |
+173,079
| New | +$46.7M |
|
12
Twist Bioscience
TWST
$1.58B
| $45.3M | 2.68% |
1,000,000
| – | – |
|
13
CareDx
CDNA
$752M
| $42.3M | 2.5% |
1,193,335
-101,000
| -8% | -$3.58M |
|
14
Revolution Medicines
RVMD
$8.59B
| $42.1M | 2.49% |
1,334,536
+15,000
| +1% | +$474K |
|
15
Adverum Biotechnologies
ADVM
$64M
| $38.9M | 2.3% |
186,500
+74,000
| +66% | +$15.5M |
|
16
Adaptive Biotechnologies
ADPT
$1.98B
| $34.5M | 2.04% |
713,125
-80,000
| -10% | -$3.87M |
|
|
17
Generation Bio
GBIO
$39.5M
| $33.8M | 2% |
+161,121
| New | +$33.8M |
|
18
Denali Therapeutics
DNLI
$1.95B
| $31.7M | 1.87% |
1,310,000
-145,000
| -10% | -$3.51M |
|
|
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $29.4M | 1.74% |
980,000
| – | – |
|
|
ONC
20
BeOne Medicines Ltd. American Depositary Shares
ONC
$35.9B
| $28.3M | 1.67% |
+150,000
| New | +$28.3M |
|
21
Allogene Therapeutics
ALLO
$264M
| $26.8M | 1.58% |
625,000
+125,000
| +25% | +$5.35M |
|
22
Fulcrum Therapeutics
FULC
$396M
| $26.4M | 1.56% |
1,441,176
+231,891
| +19% | +$4.24M |
|
23
Alector
ALEC
$286M
| $26.3M | 1.56% |
1,076,039
| – | – |
|
24
Dianthus Therapeutics
DNTH
$1.52B
| $25.1M | 1.49% |
209,127
+23,437
| +13% | +$2.82M |
|
|
AMRS
25
DELISTED
Amyris Inc.
AMRS
| $22.8M | 1.35% |
+5,349,376
| New | +$22.8M |
|